{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.7","upperLimit":"11.1","value":"6.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Overall Survival is defined as the time from the date of randomization to the date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Alisertib was administered PO at 50 mg BID for 7 days in each treatment cycle, followed by a 14-day, treatment-free period, for a 21-day cycle.","id":"OG000","title":"Alisertib"}],"paramType":"MEDIAN","populationDescription":"1 patient did not complete one cycle of treatment and 25 patients were evaluable for efficacy.","reportingStatus":"POSTED","timeFrame":"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 35 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}